The research was conducted by a team of oncologists at Washington University School of Medicine in St. Louis in partnership with the company. The investigators conducted a multiomics analysis of multiparametric MRI (mpMRI)-invisible and visible prostate cancer using BostonGene's artificial intelligence (AI)-based immunofluorescence single-cell spatial imaging and gene expression profiling.

In addition to identifying characteristics of MRI-visible, clinically significant prostate cancer, the researchers also found that tumors invisible on mpMRI were similar to normal prostate tissue. What's more, the expression profiling identified a stromal enrichment signature in mpMRI-invisible prostate cancers that correlated with better clinical outcomes, according to the researchers.

"This AI-based analytical approach could distinctly identify the molecular and cellular composition of tumor tissue," said study lead author Dr. Russell Pachynski in a statement released by BostonGene. "Integrated multiomics analysis in conjunction with mpMRI shows promise for the diagnosis and personalization of treatment options for patients with clinically significant prostate cancer."